What Biofrontera Inc. reported on November 13, 2026
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|
| Total Revenue | $12M | $9M | +32.92% |
| Profit per share | -$0.05 | -$0.57 | +91.23% |
| Free Cash Flow | -$1.7M | -$3M | +45.57% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
NewThe latest call
FetchingBiofrontera Inc. reported on November 13, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
What Biofrontera Inc. does
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with photodynamic therapy (PDT). The Company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, and, following FDA approval in September 2026, superficial basal cell carcinoma, and are in development for additional indications.
The company’s own description, as it appears at the foot of the release.
The quote, the company description and the latest quarter come from Biofrontera’s earnings press release (an Item 2.02 8-K) filed November 13, 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Read the release on EDGAR Share prices are split- and dividend-adjusted.
